Your session is about to expire
← Back to Search
Sacituzumab Govitecan + Talazoparib for Breast Cancer
Study Summary
This trial is testing a new combination therapy for metastatic triple-negative breast cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2018 Phase 1 & 2 trial • 40 Patients • NCT02116777Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the maximum capacity of participants for this clinical study?
"Indeed, the clinicaltrials.gov records demonstrate that this research is presently recruiting participants. It was initially posted on October 9th 2019 and most recently updated on October 25th 2021. Seventy-five individuals are needed at a single medical centre for enrolment in this trial."
Are there any past examinations that have focused on Talazoparib?
"Currently, 90 clinical trials are analyzing the utility of Talazoparib with 8 reaching Phase 3. Most investigations into its efficacy are being conducted in Boston, MA; however, there are 3725 separate medical centers that have joined this research effort."
In what medical scenarios is Talazoparib utilized?
"Talazoparib is commonly prescribed to treat UC 84572, but can also benefit those with breast cancer linked to a BRCA1 gene mutation and/or previous platinum-based therapy."
Are individuals being sought for enrollment in this clinical investigation?
"Affirmative. Querying clinicaltrials.gov yields that this medical trial, first posted on October 9th 2019, is currently recruiting participants - with the aim of finding 75 patients who will enrol at a single site."
Share this study with friends
Copy Link
Messenger